Table 1.

Major indications of IVIg therapy.

IVIg as replacement therapy
Primary antibody immunodeficiency*     Ataxia telangiectasia Common variable immunodeficiency syndrome Severe combined immunodeficiency Wiskott Aldrich syndrome X-linked agammaglobulinemia X-linked hyper-IgM syndrome	Secondary antibody immunodeficiency     B-cell chronic lymphocytic leukemia*     Transplantation     Multiple myeloma     Pediatric HIV infection    Drugs induced
IVIg as immunomodulatory therapy
Hematologic disorders     Immune thrombocytopenic purpura*     Auto-immune hemolytic anemia     Auto-immune neutropenia anemia     HIV-associated thrombocytopenia     Neonatal alloimmune thrombocytopenia     Parvovirus B19-associated aplasia     Dermatologic disorders     Atopic dermatitis     Bullous pemphigoid     Blistering diseases     Dermatomyositis     Epidermolysis bullosa acquisita     Immune urticaria     Kawasaki syndrome*     Mucous-membrane (cicatricial)pemphigoid     Pemphigus vulgaris     Pyoderma gangrenosum     Scleromyxoedema     Stevens-Johnson syndrome     Toxic epidermal necrolysis	Neuromuscular disorders    Birdshot retinopathy     Chronic inflammatory demyelinating polyneuropathy*     Guillain Barre syndrome     Lambert–Eaton myasthenic syndrome     Multifocal motor neuropathy*     Myasthenia gravis     Opsoclonus–myoclonus     Paraneoplastic syndromes     Persistent epilepsy disorder     Polyradiculoneuropathy Relapsing-remitting multiple sclerosis     Stiff person syndrome Ophthalmologic disorders     Autoimmune uveitis     Birdshot retinochoroidopathy     Mucous membrane pemphigoid Rheumatologic disorders     Vasculitis     Systemic lupus erythematosis     Streptococcal toxic shock syndrome

^*FDA approved indications.